For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of this treatment and Tafamidis meglumine represents a genuine change. These groundbreaking therapies preserve the transthyretin protein, preventing its destructive build-up and reducing t